Graft-Versus-Host Disease Outcomes
Graft-Versus-Host Disease Outcomes
Impact of GVHD and the Modified Rankin Scale on Patient Outcomes
Hematopoietic stem cell transplantation (HSCT) is a therapy offered to individuals with aggressive hematologic cancers such as leukemia. By and large, such cancers originate from dysfunctional
Read more
Media included
Price:
$399
Or partners log in and checkout with
Graft-Versus-Host Disease Outcomes
Graft-Versus-Host Disease Outcomes
Impact of GVHD and the Modified Rankin Scale on Patient Outcomes
Research Guides
Price
0.25 engagement credits
Order now
Complete the form below to access the Graft-Versus-Host Disease Outcomes document in Expert IQ
Subscribe and save
Your information will not be shared. View our privacy policy.